enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA-approved drug for ulcerative colitis also effective for ...

   www.aol.com/fda-approved-drug-ulcerative-colitis...

   Mirikizumab, a drug currently approved by the Food and Drug Administration (FDA) for the treatment of ulcerative colitis, also sends Crohn's disease into clinical remission, new findings suggest.

3. Targeted therapy may help treat moderate to severe ulcerative ...

   www.aol.com/targeted-therapy-may-help-treat...

   “There has been a great deal of progress in developing new, more effective and safe agents to treat inflammatory bowel diseases (Crohn’s disease and ulcerative colitis) over the last 20 years.

4. Vedolizumab - Wikipedia

   en.wikipedia.org/wiki/Vedolizumab

   Vedolizumab. Vedolizumab, sold under the brand name Entyvio, is a monoclonal antibody medication developed by Takeda Oncology for the treatment of ulcerative colitis and Crohn's disease. [5] It binds to integrin α 4 β 7 (LPAM-1, lymphocyte Peyer's patch adhesion molecule 1, a dimer of Integrin alpha-4 and Integrin beta-7), [5][6] blocking the ...

5. Upadacitinib - Wikipedia

   en.wikipedia.org/wiki/Upadacitinib

   Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. [10][11] Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes ...

6. Ozanimod - Wikipedia

   en.wikipedia.org/wiki/Ozanimod

   Ozanimod, sold under the brand name Zeposia, is an immunomodulatory medication for the treatment of relapsing multiple sclerosis and ulcerative colitis. [3] [4] [6] [7] It acts as a sphingosine-1-phosphate receptor (S1PR) agonist, sequestering lymphocytes to peripheral lymphoid organs and away from their sites of chronic inflammation.

7. Visilizumab - Wikipedia

   en.wikipedia.org/wiki/Visilizumab

   Visilizumab. Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells.